Afuresertib
| CAS No. | 1047644-62-1 | Cat. No. | BCP08435 |
| Name | Afuresertib | ||
| Synonyms | GSK 2110183C;GSK2110183C;GSK-2110183C; | ||
| Formula | C18H17Cl2FN4OS | M. Wt | 427.32 |
| Description | Afuresertib (GSK2110183) shows concentration-dependent effect on multiple AKT substrate phosphorylation levels, including GSK3β, PRAS40, FOXO and Caspase 9 in both BT474 and LNCaP cell lines. GSK2110183 consistently has potent anti-proliferative effects on a variety of hematological malignancies. Overall 65% of the hematological cell lines are sensitive to GSK2110183 (EC50<1 μM). Among solid tumor cell lines, 21% have EC50<1 μM in response to GSK2110183. In Vivo Mice bearing BT474 breast tumor xenografts are dosed orally with either vehicle or GSK2110183 at 10, 30 or 100 mg/kg daily for 21 days which results in 8, 37 and 61% tumor growth inhibition (TGI), respectively. | ||
| Pathways | PI3K/Akt/mTOR | ||
| Targets | AKT | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.